

## 2022 OPA Midyear Meeting Learning Objectives

### **ACPE #0129-0000-22-101-L01-P**

#### **Allergic Rhinitis: Impacting Your Patients with Asthma**

*Logan Hunkus, PharmD and Christopher Hernandez, PharmD*

At the completion of this activity, the participant will be able to:

1. describe the clinical presentation of seasonal allergies;
2. analyze seasonal allergy treatment options in the presence of asthma; and
3. apply necessary medication adjustments needed to treat asthma during allergy season.

### **ACPE #0129-0000-22-102-L01-P**

#### **Newsworthy Nicotine: Translating New Regulations into Practice**

*Michael J. Rush, PharmD, MBA, BCACP, CDCES, NCTTP*

At the completion of this activity, the participant will be able to:

1. discuss the pathophysiology of nicotine addiction;
2. define Electronic Nicotine Delivery Systems (ENDS) and provide examples; and
3. review recent Food and Drug Administration (FDA) regulatory actions and the potential impact these regulations could have on pharmacy practice.

### **ACPE #0129-0000-22-103-L99-P**

#### **Wellness in the Workplace- We are in this together!**

*Kyle A Gustafson, PharmD, BCPS, BCCCP and Jaclyn Boyle, PharmD, MS, MBA, BCACP*

At the completion of this activity, the participant will be able to:

1. review the Ohio Pharmacy Workforce Survey data;
2. apply simple daily practices to improve workplace wellness; and
3. formulate a plan to critically evaluate one's daily workload.

### **ACPE #0129-0000-22-104-L05-P**

#### **Application of Pharmacogenomics Guidelines to Improve Medication Efficacy and Safety**

*David F. Kisor, BS, PharmD, R.Ph., FCP*

At the completion of this activity, the participant will be able to:

1. define pharmacogenomics and related standardized terms;
2. explain the application of pharmacogenomics in optimizing medication efficacy;
3. explain how pharmacogenomics can be used to help minimize the risk of or avoid adverse drug reactions altogether; and
4. identify the sources of evidence-based clinical pharmacogenomics guidelines.

### **ACPE #0129-0000-22-105-L01-P**

#### **Kidneys, Kinetics, Drug Dosing – Oh My!**

*Maria (Pruchnicki) Coyle, PharmD, FCCP, BCPS, BCACP, CLS*

At the completion of this activity, the participant will be able to:

1. review the 2021 Report by the NKF/ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases;

2. identify preferred methods for assessing eGFR from available biomarkers (SCr and cystatin C) and using the new race-free approach;
3. discuss current practices and challenges in medication dosing in patients with chronic kidney disease, including common examples; and
4. apply recent recommendations to various patient case scenarios.

**ACPE #0129-0000-22-106-L99-P**

**Pharmacy Deserts: Access and Barriers**

*Sarah E. Adkins, PharmD, BCACP*

At the completion of this activity, the participant will be able to:

1. discuss already known barriers to health care;
2. recognize what is being done to break down barriers; and
3. describe how grassroots efforts are effective at building accessibility.